UBS Group’s Chembio diagnostics, Inc. CEMI Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2023
Q2 | – | Sell |
-18,681
| Closed | -$8.26K | – | 10459 |
|
|
2023
Q1 | $8.26K | Buy |
+18,681
| New | +$7.32K | ﹤0.01% | 7740 |
|
|
2022
Q1 | – | Sell |
-10,294
| Closed | -$12K | – | 11637 |
|
|
2021
Q4 | $12K | Buy |
+10,294
| New | +$21K | ﹤0.01% | 8647 |
|
|
2021
Q3 | – | Sell |
-2,940
| Closed | -$9K | – | 10842 |
|
|
2021
Q2 | $9K | Sell |
2,940
-3,874
| -57% | -$13.5K | ﹤0.01% | 8213 |
|
|
2021
Q1 | $23K | Buy |
6,814
+1,816
| +36% | +$10.1K | ﹤0.01% | 7275 |
|
|
2020
Q4 | $24K | Buy |
4,998
+3,998
| +400% | +$20.6K | ﹤0.01% | 6829 |
|
|
2020
Q3 | $5K | Sell |
1,000
-7,103
| -88% | -$33.6K | ﹤0.01% | 7374 |
|
|
2020
Q2 | $27K | Sell |
8,103
-6,940
| -46% | -$65.9K | ﹤0.01% | 6366 |
|
|
2020
Q1 | $78K | Sell |
15,043
-11,771
| -44% | -$47.6K | ﹤0.01% | 5495 |
|
|
2019
Q4 | $122K | Sell |
26,814
-79
| -0.3% | -$385 | ﹤0.01% | 5903 |
|
|
2019
Q3 | $165K | Buy |
26,893
+272
| +1% | +$1.62K | ﹤0.01% | 5404 |
|
|
2019
Q2 | $162K | Buy |
26,621
+2,621
| +11% | +$17.7K | ﹤0.01% | 5052 |
|
|
2019
Q1 | $133K | Buy |
24,000
+19,840
| +477% | +$129K | ﹤0.01% | 4876 |
|
|
2018
Q4 | $24K | Buy |
4,160
+680
| +20% | +$5.01K | ﹤0.01% | 6661 |
|
|
2018
Q3 | $36K | Buy |
3,480
+894
| +35% | +$9.6K | ﹤0.01% | 6421 |
|
|
2018
Q2 | $29K | Buy |
2,586
+286
| +12% | +$2.57K | ﹤0.01% | 6429 |
|
|
2018
Q1 | $18K | Sell |
2,300
-678
| -23% | -$5.42K | ﹤0.01% | 6491 |
|
|
2017
Q4 | $25K | Sell |
2,978
-8,482
| -74% | -$57.4K | ﹤0.01% | 6398 |
|
|
2017
Q3 | $71K | Buy |
11,460
+143
| +1% | +$880 | ﹤0.01% | 5557 |
|
|
2017
Q2 | $68K | Buy |
11,317
+2,017
| +22% | +$12.6K | ﹤0.01% | 5446 |
|
|
2017
Q1 | $49K | Sell |
9,300
-7,527
| -45% | -$43.8K | ﹤0.01% | 5545 |
|
|
2016
Q4 | $114K | Buy |
16,827
+458
| +3% | +$3.17K | ﹤0.01% | 5202 |
|
|
2016
Q3 | $121K | Buy |
16,369
+1,908
| +13% | +$13.7K | ﹤0.01% | 4889 |
|
|
2016
Q2 | $119K | Buy |
14,461
+4,304
| +42% | +$33.5K | ﹤0.01% | 4912 |
|
|
2016
Q1 | $61K | Buy |
10,157
+7,857
| +342% | +$40.6K | ﹤0.01% | 5347 |
|
|
2015
Q4 | $12K | Sell |
2,300
-1,720
| -43% | -$8.62K | ﹤0.01% | 7204 |
|
|
2015
Q3 | $16K | Buy |
4,020
+833
| +26% | +$3.77K | ﹤0.01% | 6952 |
|
|
2015
Q2 | $16K | Buy |
3,187
+3,162
| +12,648% | +$14.6K | ﹤0.01% | 7117 |
|
|
2015
Q1 | $0 | Sell |
25
-4,013
| -99% | -$15.8K | ﹤0.01% | 10183 |
|
|
2014
Q4 | $16K | Buy |
+4,038
| New | +$16.7K | ﹤0.01% | 7999 |
|
Other funds holding CEMI
UBS Group's CEMI Position: Q2 2023 in Review
UBS Group sold out of Chembio diagnostics, Inc. (CEMI) in Q2 2023, closing a stake of 18,681 shares — an estimated $8.26K sold.
UBS Group first reported a position in CEMI in Q4 2014 and held it in 29 quarters. The position peaked at $165K in Q3 2019. 1 fund tracked by Wall St. Rank holds CEMI as of Q2 2023.
- UBS Group reported no remaining Chembio diagnostics, Inc. position as of Q2 2023 after selling out during the quarter.
- UBS Group sold 18,681 Chembio diagnostics, Inc. shares in Q2 2023, an estimated $8.26K.
- UBS Group first reported a position in Chembio diagnostics, Inc. in Q4 2014 and held it in 29 quarters.
- UBS Group's Chembio diagnostics, Inc. position peaked at $165K in Q3 2019.
- 1 fund tracked by Wall St. Rank held Chembio diagnostics, Inc. as of Q2 2023.
Based on UBS Group's 13F filing for Q2 2023, filed 11 Aug 2023.